RODMAN&RENSHAW Analyst Recommendations & Stock Picks This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at RODMAN&RENSHAW. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by RODMAN&RENSHAW. Country All Countries United States(NYSE & NASDAQ) United States(All Exchanges) Canada United Kingdom Sector All Sectors Aerospace Auto/Tires/Trucks Basic Materials Business Services Computer and Technology Construction Consumer Discretionary Consumer Goods Consumer Staples Finance Industrial Products Medical Miscellaneous Multi-Sector Conglomerates Oils/Energy Retail/Wholesale Services Transportation Utilities All Market Caps Large Cap ($10B+) Medium Cap ($2B-$10B) Small Cap (<$2B) Market Cap MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Export to Excel CompanyCurrent PriceRating DateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActionsATRAAtara Biotherapeutics$11.40+14.8%12/20/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyN/AView details for RODMAN&RENSHAW rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024HURATuHURA Biosciences$4.48+12.0%12/19/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyN/AView details for RODMAN&RENSHAW rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024RMTIRockwell Medical$2.08+1.5%11/14/2024Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyN/AView details for RODMAN&RENSHAW rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024OMEROmeros$10.31+0.7%11/14/2024Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyN/AView details for RODMAN&RENSHAW rating of Omeros (NASDAQ:OMER) on 11/14/2024EPRXEupraxia Pharmaceuticals$2.99-0.3%11/14/2024Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyN/AView details for RODMAN&RENSHAW rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024ACHVAchieve Life Sciences$3.69-3.4%11/14/2024Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyN/AView details for RODMAN&RENSHAW rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024BCAXBicara Therapeutics$17.59+6.0%11/5/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyLowView details for RODMAN&RENSHAW rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024QNCXQuince Therapeutics$1.78+1.1%10/29/2024Upgraded byRODMAN&RENSHAWAnalyst E. PirosStrong-BuyHighView details for RODMAN&RENSHAW rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024ANROAlto Neuroscience$3.89+4.6%10/23/2024Downgraded byRODMAN&RENSHAWAnalyst E. PirosStrong-Buy -> HoldMediumView details for RODMAN&RENSHAW rating of Alto Neuroscience (NYSE:ANRO) on 10/23/2024NKTXNkarta$2.37+7.7%10/9/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyHighView details for RODMAN&RENSHAW rating of Nkarta (NASDAQ:NKTX) on 10/9/2024KYTXKyverna Therapeutics$4.00+3.4%10/9/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyHighView details for RODMAN&RENSHAW rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024MIRAMIRA Pharmaceuticals$1.06+6.0%9/30/2024Upgraded byRODMAN&RENSHAWAnalyst E. PirosStrong-BuyLowView details for RODMAN&RENSHAW rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024BMEABiomea Fusion$4.23+3.7%9/26/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyLowView details for RODMAN&RENSHAW rating of Biomea Fusion (NASDAQ:BMEA) on 9/26/2024 MarketBeat Community Rating for RODMAN&RENSHAWCommunity Ranking: 2.5 out of 5 (2.5 of 5 stars)Outperform Votes: 5,399 (Vote Outperform)Underperform Votes: 5,414 (Vote Underperform)Total Votes: 10,813MarketBeat's community ratings are surveys of what our community members think about RODMAN&RENSHAW and other research firms. Vote "Outperform" if you believe RODMAN&RENSHAW's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RODMAN&RENSHAW's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days. Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
